The role of the MPL receptor in myeloproliferative disorders

Leukemia

Volumn 12, Issue SUPPL. 1, 1998, Pages

  Kaushansky, Kenneth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myelogenous leukemia; MPL receptor; Myeloproliferative disorders; Platelet donation; Thrombocytopenia; Thrombopoietin

Indexed keywords

CYTOKINE RECEPTOR; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CONFERENCE PAPER; GENE MUTATION; HUMAN; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA;

EID: 0031783689     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
2. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-538.
3. Vigon I, Mornon J-P, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci 1992;89:5640-5644.
4. Ziegler FC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994;84:4045-4052.
5. Cocault L, Bouscary D, Le Bousse Kerdiles C, et al. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood 1996;88:1656-1665.
6. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood 1993;82:877-883.
7. Sitnicka E, Lin N, Priestly GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87:4998-5005.
8. Ku H, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the MPL receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87:4544-4551.
9. Carver-Moore K, Broxmeyer HE, Luoh S-M, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin - and c-mpl - deficient mice. Blood 1996;88:803-808.
10. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 1998;95:1195-1200.
11. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995;14:5569-5578.
12. Onishi M, Kinoshita S, Morikawa A, et al. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324-329.
13. Motoji T, Takanashi M, Motomura S, et al. Growth stimulatory effect of acute myelogenous leukaemia. Br J Hematol 1996;94:513-516.
14. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (MPL ligand): reversal of disease by bone marrow transplantation. Blood 1996;88:402-409.
15. Wiestner A, Schlemper RJ, Van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998;18:49-52.
16. Kondo M, Okabe M, Sanada S, et al. Identification of TPO gene mutation in familial essential thrombocythemia. Blood 1997;90 (suppl 1):54a. Abstract 231.
17. Quentmeier H, Zaborski M, Graf G, Ludwig WD, Drexler HG. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. Leukemia 1996;10:297-310.
18. Matsumura I, Kanakura Y, Ikeda H, et al. Coexpression of thrombopoietin and c-mpl genes in human acute myeloblastic leukemia cells. Leukemia 1996b;10:91-94.
19. Matsumura I, Kanakura Y, Kato T, et al. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 1995;86:703-709.
20. Matsumura I, Kanakura Y, Kato T, et al. The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood 1996a;88:3074-3082.
21. Li Y, Hetet G, Kiladjian J-J, Gardin C, Grandchamp B, Briere J. Proto-oncogene c-mpl is involved in spontaneous megakaryocy-topoiesis in myeloproliferative disorders. Br J Haematol 1996;92:60-66.
22. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-409.
23. Archimbaud E, Ottmann O, Liu Yin JA, et al. A randomised, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukaemia (AML): Early results. p 447A, Abstract No. 1778.
24. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-681.
25. Vadhan-Raj S, Verschraegen C, McGarry L, et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (c)-induced thrombocytopenia in patients with gynecologic maliggnancy. Blood 1997;90 (suppl 1):580a.
26. Kuter D, McCullough J, Romo J, et al. Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases circulating PLT counts (CTS) and PLT apheresis yields and increases platelet increments in recipients of PLT transfusions. Abstract no. 2579.